Drug Profile

Research programme: dendrimer-based cancer therapeutics - AstraZeneca

Alternative Names: Antibody-targeted DEP^® conjugate; DEP^® products - AstraZeneca; Targeted DEP™ conjugates

Latest Information Update: 28 Dec 2019

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator AstraZeneca
Class Dendrimers; Drug conjugates
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported Cancer

Most Recent Events

28 Dec 2019 No recent reports of development identified for preclinical development in Cancer in Sweden
29 Aug 2019 Starpharma files for patent protection for Targeted DEP^® conjugate
04 Jun 2019 StarPharma and AstraZeneca agree to co-develop Dendrimer Enhanced Product (DEP®) version of an undisclosed AstraZeneca marketed oncology medicine

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com